Prolactin and antipsychotic medications: mechanism of action.
about
The glial growth factors deficiency and synaptic destabilization hypothesis of schizophreniaThe substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophreniaThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Classics in Chemical Neuroscience: Aripiprazole.Risk of osteoporosis and fracture incidence in patients on antipsychotic medication.Ziprasidone-induced galactorrhea in an adolescent female: a case reportZiprasidone, a new atypical antipsychotic drug.What can we learn from rodents about prolactin in humans?Pharmacological causes of hyperprolactinemiaSexual dysfunction in outpatients with schizophrenia in Turkey: a cross-sectional study.Health problems of women with severe mental illness.Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemiaReduced Fertility and Fecundity among Patients with Bipolar I Disorder and Schizophrenia in Egypt.Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials.Antipsychotic-induced euprolactinemic galactorrhea in an adolescent girl: a case report.Safety and tolerability of antipsychotic polypharmacy.A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case reportBipolar disorder: historic perspective, current pharmacologic treatment options and a review of quetiapine.Long-term use of atypical antipsychotics in bipolar disorder.Pulmonary embolism related to amisulpride treatment: a case reportReview of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophreniaRisperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia.Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based studyImproving physical health monitoring for patients with chronic mental health problems who receive antipsychotic medications.Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study.Antipsychotic use and the risk of hip/femur fracture: a population-based case-control studyEfficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.Hormone profile in acute psychotic disorders: A cross-sectional comparison of serum hormone concentrations in treated and untreated male patients with schizophrenia.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.Antipsychotic drugs and obesity: is prolactin involved?Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study.Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine.No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics.Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.High bone turnover but normal bone mineral density in women suffering from schizophrenia.Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research.
P2860
Q24798030-DDD1B078-734C-4B38-927F-6A1A204CC48AQ28210979-C9A8DF31-59E6-44E4-A089-71050506F89FQ33619940-506AA5CE-E585-4FE3-963D-0756A0D35943Q33866125-18B11234-C75A-4DD6-B0C2-C15C453D39A8Q34026011-2B6A9282-4639-4D9A-85BF-1B0E0232F986Q34163645-18A55C6F-9705-4550-8E10-A7718451C37BQ34278844-DD15ACE2-6D78-427E-9DE1-A820916860EAQ34721567-EB7E08F2-7EBB-4CE8-85A3-E087A2EE7A6DQ34778045-158A04E9-A1B7-40C8-8CCB-2605CE9FEFB9Q35029078-2118DA4F-DD70-44C7-837E-CA68996A2A70Q35151745-BB3D6961-809B-43A4-B9AC-E897917A1FDDQ35167958-EF557E44-11BA-410E-8464-FC265C7919A0Q35238338-E3EEEF56-F984-4D7F-8BD5-F58D37EE9DCAQ35729122-3149A6D9-20C2-46E5-A333-EA13FA4C506FQ35977750-A3353A3E-F2FD-45A6-BADC-202AB7E10844Q36062421-B3B4848C-6AD3-4183-8E75-1854F69E97BFQ36322256-CE7ABB00-1B1B-4D9F-8EF4-E0E215D56E1CQ36390795-362D7ABD-6D8D-4AB3-AC01-80C0D196BE36Q36545075-3245EBB2-6498-4245-89C6-AAA0E1C13A4AQ36692244-82B1EF6E-4F33-4971-9195-2214B79D227FQ36836750-362F4D37-8CF5-449A-B1CC-06FEFD416F98Q36873892-400439E7-E04C-4F77-80BA-BE4D39A535E9Q36910550-0F9C9D77-BB46-432D-99C7-38BEEF5CB685Q37078928-D392E72D-E35A-45B2-A486-B55F5158975BQ37112276-D33C92E5-CED7-458A-9F5C-AF6296D40295Q37195748-3FF8CC79-2707-4A45-BBA1-1025E6C4175BQ37307572-C0E5228F-8A07-4050-8FCB-9D697A6892C8Q37308723-CEB45282-339E-471B-91A2-64F55A5EDDF4Q37596280-CED30128-8256-48E7-AABC-88786A7E3590Q37663522-555B76A1-3A41-42F3-9C1F-17E53FCA4F94Q37983747-CB658DF5-14B2-48CD-8A35-6EE09363C983Q38815462-22A932B9-F431-4E2B-A6A6-DB0B18D3B109Q40669926-B8BF0537-E530-4B9C-847B-BC4A093F6794Q41589392-C629E392-31A7-4B03-8A6A-6210D6DC2989Q42403825-CC024EDA-90DC-49F2-A540-69D4E8A23DACQ44292357-353A2C0B-19C8-47B9-9C76-46F89179B819Q45002987-848AE0E5-6F63-4DEA-A3FA-0BC230B59B21Q45406181-B908A917-20A5-4A18-834B-CDFE234DEB51Q46351516-8AE46A18-F5FE-4D48-AE8D-888752951758Q47645310-C38D6E07-A5D7-44A1-856E-80A4419B7442
P2860
Prolactin and antipsychotic medications: mechanism of action.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prolactin and antipsychotic medications: mechanism of action.
@ast
Prolactin and antipsychotic medications: mechanism of action.
@en
Prolactin and antipsychotic medications: mechanism of action.
@nl
type
label
Prolactin and antipsychotic medications: mechanism of action.
@ast
Prolactin and antipsychotic medications: mechanism of action.
@en
Prolactin and antipsychotic medications: mechanism of action.
@nl
prefLabel
Prolactin and antipsychotic medications: mechanism of action.
@ast
Prolactin and antipsychotic medications: mechanism of action.
@en
Prolactin and antipsychotic medications: mechanism of action.
@nl
P1476
Prolactin and antipsychotic medications: mechanism of action.
@en
P2093
P304
P356
10.1016/S0920-9964(98)00158-3
P407
P478
P577
1999-03-01T00:00:00Z